Search PubMed⌕ Search

Biomedical subjects

K Kusugami

Publications and source records attributed to K Kusugami.

77 records · Page 5Linked to original sources
PubMedDate not supplied

A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer.

BACKGROUND: The aim of this multicentric trial was to determine the clinical toxicities and antitumor effects of a chemotherapy regimen of S-1 combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer. PATIENTS AND METHODS: Forty-two patients were entered into the study. S-1 (80 mg/m2) was administered orally daily for 14 consecutive days and 24-h infusion of cisplatin (70 mg/m2) was administered on day 8 of every 28-day cycle. RESULTS: The overall response rate was 50% and complete response rate was 5%. The most common adverse event was leucopenia, which occurred with grade 3 in 7 patients (16.6%) and grade 4 in 2 patients (4.8%). Non-hematological adverse events were generally mild. The median survival time was 342 days. The 2-year survival rate was 22.9%. CONCLUSION: This combination chemotherapy is active, convenient and well tolerated in patients with high-grade advanced gastric cancer.

Adult↗
PubMedDate not supplied

Effect of histamine on thyrotropin-releasing hormone and somatostatin secretion in rat stomach.

BACKGROUND/AIMS: Histamine plays an important role in gastric function, and the histaminergic system is involved in the regulation of neuropeptides and gastric acid secretion. METHODOLOGY: We investigated the effect of histamine and histamine receptor antagonist (HRA) on the intraluminal secretion of thyrotropin-releasing hormone (TRH) and somatostatin (SOM) using a rat luminal perfusion model. RESULTS: Intravenous administration of histamine caused an increase in TRH secretion and a decrease in SOM secretion preceding a decrease in pH in the perfusate. When the total contents of TRH and SOM in the perfusate were calculated after administration of histamine, the effect of histamine was found to be dose-dependent in both neuropeptide secretions. Under basal conditions, neither H1RA, H2RA, nor H3RA caused changes in TRH secretion into the perfusate. In contrast, H2RA and H3RA yielded an increase in basal SOM secretion. When administered before the injection of histamine, H2RA caused a complete inhibition of histamine-induced changes in TRH and SOM secretion. Preadministration of H3RA also induced a weak but significant inhibition of the changes in neuropeptide secretion. CONCLUSION: It was concluded that paracrine pathways do exist among histamine, TRH, and SOM in the regulation of gastric acid secretion.

Animals↗